ViGenCell Inc. (KOSDAQ:308080)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,070
-140 (-1.25%)
At close: Apr 28, 2026
249.76%
Market Cap 226.93B
Revenue (ttm) 278.95M
Net Income (ttm) -12.56B
Shares Out 20.50M
EPS (ttm) -650.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,835,357
Average Volume 1,563,155
Open 11,500
Previous Close 11,210
Day's Range 10,560 - 11,940
52-Week Range 2,760 - 17,360
Beta 0.84
RSI 82.71
Earnings Date n/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 64
Stock Exchange KOSDAQ
Ticker Symbol 308080
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.